Key points from article :
San Francisco startup Loyal is rethinking the concept of longevity and starting with man’s best friend.
Due to dogs being a good model for human health, many studies on human diseases are done on dogs.
Loyal is intending to improve healthspan and lifespan in dogs, that research will uncover more about how to do the same in humans.
"A dog’s lifespan is similar to human’s due to proximity - shared environmental factors, sometimes same diet and can develop same aging diseases as humans." - Celine Halioua, Loyal CEO.
Building an animal pharmaceutical company for dogs, and eventually parlay that R&D into products for humans.
To date, the company has raised $38 million since being founded in 2019.
Funding will focus on its products: to expand the life of large breed animals, and improve cognitive function.
Will undergo clinical studies next year, working toward U.S. FDA approval, Halioua said.
Loyal will then focus on building a consumer brand selling directly to both veterinarians and pet parents.
